4.6 Article

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Microbiology

Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro

Nathan E. Stone et al.

Summary: Stenoparib, a PARP inhibitor currently in phase II clinical trials for ovarian cancer treatment, demonstrates dose-dependent suppression of SARS-CoV-2 and other coronaviruses in vitro, potentially synergistic with remdesivir. Its established safety and dosage in humans make it a promising candidate for rapid repurposing in the fight against COVID-19.
Article Multidisciplinary Sciences

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

Goran Kokic et al.

Summary: Remdesivir is the only FDA-approved drug for treating COVID-19 patients, working by inhibiting the RNA-dependent RNA polymerase (RdRp) of coronaviruses. It hinders RNA synthesis and impairs proofreading by the viral 3'-exonuclease, leading to a stalled replication process.

NATURE COMMUNICATIONS (2021)

Article Biochemistry & Molecular Biology

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

Florian Kabinger et al.

Summary: Molnupiravir is an oral antiviral drug candidate that increases viral RNA mutations frequency and inhibits replication of SARS-CoV-2 by altering the substrate preference of RdRp. This two-step mutagenesis mechanism can explain the broad-spectrum antiviral activity of molnupiravir, making it a promising COVID-19 treatment option.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2021)

Article Cell Biology

Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell

Maritza Puray-Chavez et al.

Summary: This study identifies human H522 lung adenocarcinoma cells as permissive to SARS-CoV-2 infection and reveals the importance of the E484D S variant for infection. Vaccinated individuals' sera block the alternative entry mechanism, whereas convalescent sera are less effective.

CELL REPORTS (2021)

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Virology

Poly-ADP Ribosyl Polymerase 1 (PARP1) Regulates Influenza A Virus Polymerase

Liset Westera et al.

ADVANCES IN VIROLOGY (2019)

Article Pharmacology & Pharmacy

Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein

Jian Lei et al.

ANTIVIRAL RESEARCH (2018)

Article Biochemistry & Molecular Biology

PARP12 suppresses Zika virus infection through PARP-dependent degradation of NS1 and NS3 viral proteins

Lili Li et al.

SCIENCE SIGNALING (2018)

Article Virology

The coronavirus nucleocapsid protein is ADP-ribosylated

Matthew E. Grunewald et al.

VIROLOGY (2018)

Article Biochemistry & Molecular Biology

PARP12 suppresses Zika virus infection through PARP-dependent degradation of NS1 and NS3 viral proteins

Lili Li et al.

SCIENCE SIGNALING (2018)

Article Chemistry, Medicinal

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors

Ann-Gerd Thorsell et al.

JOURNAL OF MEDICINAL CHEMISTRY (2017)

Article Biochemistry & Molecular Biology

Poly(ADP-ribosyl)ation-dependent Transient Chromatin Decondensation and Histone Displacement following Laser Microirradiation

Hilmar Strickfaden et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2016)

Article Microbiology

Virus-Host Interactions and the ARTD/PARP Family of Enzymes

Chad V. Kuny et al.

PLOS PATHOGENS (2016)

Article Multidisciplinary Sciences

Dose-Response Analysis Using R

Christian Ritz et al.

PLOS ONE (2015)

Review Virology

The Coronavirus Nucleocapsid Is a Multifunctional Protein

Ruth McBride et al.

VIRUSES-BASEL (2014)